Evolving Requirements of Care within the Systemic Remedy of Metastatic Urothelial Most cancers

As of 2024, bladder most cancers is the sixth most typical most cancers prognosis in adults in the USA.¹ It’s extra frequent in males than ladies and primarily impacts individuals above the age of 55 years.² The Nationwide Most cancers Institute estimates that greater than 16,000 Individuals will die of bladder most cancers in 2024, with greater than 90% of bladder cancers in Europe and the USA being of urothelial histology.^2,3 Remedy of urothelial most cancers can differ dramatically between early stage localized illness and regionally superior or metastatic illness, and there are completely different roles for surgical procedure, radiation, and regionally administered or systemic antineoplastic remedies based mostly on the stage of prognosis, in addition to affected person targets, preferences, efficiency standing, organ operate, and different medical comorbidities.⁴

Systemic standard cytotoxic chemotherapy, extra particularly platinum-containing chemotherapy, has been the usual of care first-line therapy in eligible sufferers with regionally superior/metastatic urothelial most cancers (LA/mUC) for many years.⁴ Cisplatin eligibility has been studied and outlined to assist decision-making for choice of therapy.⁵ Subsequent therapies after first-line therapy traditionally have included different cytotoxic chemotherapy.^4,6 Novel mechanisms of motion past conventional cytotoxic chemotherapy have been developed and studied, together with small-molecule focused inhibitors, immunotherapy, antibody drug conjugates (ADCs), or combos of those with chemotherapy. As such, the usual of take care of preliminary and subsequent administration of this illness has modified quickly lately.

This overview will talk about the latest evolution within the therapy of LA/mUC, novel therapies and regimens together with their function in therapy of the illness and concerns for pharmacists and different clinicians when managing these sufferers.

Erdafitinib

Erdafitinib (Balversa; Janssen Biotech, Inc)is a pan-fibroblast development issue receptor (FGFR) inhibitor presently indicated for the therapy of LA/mUC with vulnerable FGFR3 genetic alterations that has progressed following not less than 1 prior systemic remedy.⁷ Erdafitinib was initially authorized via the FDA’s accelerated approval program in 2019 for sufferers with LA/mUC harboring both FGFR2 or FGFR3 mutation or fusion/rearrangement based mostly on the excessive total response charge (ORR) from the only arm part 2, open-label BLC2001 trial.^8,9 Outcomes from cohort 1 of the confirmatory part 3 THOR trial (NCT03390504) demonstrated the numerous total survival (OS) and progression-free survival (PFS) advantage of erdafitinib vs docetaxel or vinflunine chemotherapy, particularly in sufferers who had obtained prior anti–programmed cell dying protein 1 (PD-1) or anti–programmed dying ligand 1 (PD-L1) brokers.¹⁰ Because of this, the FDA approval presently doesn’t suggest erdafitinib be used previous to PD-1/PD-L1 inhibitors if sufferers are eligible to obtain them.⁷ Cohort 2 of the THOR trial randomized PD-1/PD-L1-naive sufferers to obtain erdafitinib or pembrolizumab and reported no statistically vital distinction in OS, so it stays to be seen if the FDA will revise its approval of erdafitinib.¹¹ Primarily based on cohort 1 of the THOR trial, the complete approval of erdafitinib is restricted to FGFR3 alterations solely.⁷

Erdafitinib has a novel dose titration owing to the pharmacodynamic impact on serum phosphate ranges.⁷ Sufferers are began at 8 mg as soon as each day and phosphate stage ought to be measured 14 to 21 days after remedy initiation.⁷ The dose ought to be elevated to 9 mg as soon as each day if phosphate stage is lower than 9.0 mg/dL and there aren’t any ocular problems or grade 2 or larger adversarial results (AEs).⁷ Moreover, the dose ought to be diminished by increments of 1 mg per discount with out there tablet sizes to a minimal of 4 mg each day for AEs requiring dose modification.⁷ Extreme AEs occurred in 45% of sufferers handled with erdafitinib within the THOR trial, the most typical being palmar–plantar erythrodysesthesia syndrome (9.6%), stomatitis (8.1%), onycholysis (5.9%), and hyperphosphatemia (5.2%).¹⁰ Sufferers ought to obtain routine ophthalmological examinations at baseline and through remedy, and ought to be endorsed to report imaginative and prescient adjustments to detect and intervene on ocular problems together with central serous retinopathy/retinal pigment epithelial detachment.⁷

A nutritionist or dietician could assist optimize sufferers’ diets if hyperphosphatemia happens. Erdafitinib is primarily metabolized by cytochrome P450 (CYP) 3A4 and 3C9 and is an inhibitor of P-glycoprotein.⁷

Immune Checkpoint Inhibitors

Antibody inhibitors of PD-1 or PD-L1 are collectively often called immune checkpoint inhibitors (ICI) attributable to their mechanism of inducing T cell recognition and destruction of cancerous cells.¹² At the moment, nivolumab (Opdivo; Bristol Myers Squibb), avelumab (Bavencio; EMD Serono), and pembrolizumab (Keytruda; Merck & Co, Inc) are authorized to be used in metastatic urothelial most cancers. They’re every authorized as single-agent therapy following development throughout or following platinum-containing chemotherapy, however this overview will talk about newer approvals and developments of utilizing ICI in metastatic UC particularly, reminiscent of mixture therapy or upkeep. Every agent has a particular dose and frequency of administration that ought to be adhered to; dose maintain/delay or discontinuation could happen, however no dose discount is allowed. Weight-based doses have been typically utilized in scientific trials however flat doses no matter weight are authorized for ICIs as effectively and will be utilized.

AEs of ICIs are distinct from, but typically resemble these of conventional cytotoxic anti-cancer remedies.^13,14 These immunotherapy-related AEs (IrAEs) are presently finest understood as a consequence of immune system ‘auto’-reactivity, however mechanisms are advanced and never exactly understood.¹⁵ IrAEs are numerous and may have an effect on practically any organ system within the physique, and examples embrace pores and skin rash (dermatitis), diarrhea (colitis), hypo/hyperthyroidism, laboratory adjustments suggestive of hepatitis, hardly ever myocarditis, and quite a few others.^13,14 Clinicians ought to be accustomed to ICI and different immunotherapies to handle these IrAEs appropriately. Organizations such because the Nationwide Complete Most cancers Community, the American Society of Scientific Oncology (ASCO), and Society for Immunotherapy of Most cancers have clinician assets for managing IrAEs in addition to training assets for sufferers.^15,16

Avelumab as Upkeep Remedy

Avelumab, a PD-L1 inhibitor, is indicated as swap upkeep therapy for LA/mUC that didn’t progress on first-line platinum-containing chemotherapy based mostly on the part 3 JAVELIN Bladder (JB) 100 trial (NCT02603432).^17,18 Sufferers don’t must have their tumor examined for PD-L1 positivity, microsatellite instability-high/poor mismatch restore (MSI-H/dMMR), or excessive tumor mutational burden (TMB) to be eligible for avelumab.¹⁷ Gemcitabine plus cisplatin or carboplatin got for 4 to six cycles as induction platinum-containing chemotherapy within the JB100 trial, although given the relative comparable profit of those regimens when in comparison with methotrexate, vinblastine, doxorubicin, and cisplatin given in an “accelerated” or “dose-dense” method, it’s applicable to think about avelumab upkeep therapy following any of the above platinum-containing regimens.^4,18 Avelumab was administered till development or unacceptable toxicity following completion of 4 to six cycles of chemotherapy.18 As a result of threat of infusion response, sufferers ought to obtain an antihistamine and acetaminophen previous to not less than the primary 4 infusions of avelumab and be monitored intently through the infusion.¹⁷

Nivolumab

Nivolumab, a PD-1 inhibitor, was authorized in March 2024 to be given together with cisplatin and gemcitabine in cisplatin-eligible sufferers as first-line therapy of LA/mUC based mostly on the CheckMate 901 trial (NCT03036098).^19,20 CheckMate 901 was a part 3 open-label trial evaluating the addition of nivolumab to cisplatin/gemcitabine in opposition to such chemotherapy alone.²⁰ Previous to the CheckMate 901 trial, no novel agent added in concurrent mixture to first-line platinum-containing chemotherapy had demonstrated a big OS profit, together with atezolizumab (IMvigor130 trial [NCT02807636]) or pembrolizumab (KEYNOTE-361 trial [NCT02853305]).^21,22 Whereas nivolumab is given each 21 days to match the 21-day cycle size of cisplatin plus gemcitabine, it may be given each 14 or 28 days as continuation upkeep following completion of chemotherapy till development or unacceptable toxicity. Sufferers don’t must have the tumor examined for PD-L1 positivity, MSI-H/dMMR, or excessive TMB to be eligible.²³ Pre-medications will not be routinely advisable upfront, aside from these given to stop AEs from cisplatin and gemcitabine.

Enfortumab Vedotin-efjv

Enfortumab vedotin-efjv (EV, Padcev; Seagen Inc) is the first-in-class and solely ADC of the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) linked to the nectin-4 concentrating on antibody enfortumab.²⁴ EV first obtained accelerated approval in 2019 for therapy of mUC that progressed on platinum-containing chemotherapy and PD-1/PD-L1 inhibitor based mostly on the only arm part 2 EV-201 trial (NCT03219333).^25,26 Additional information from a second cohort demonstrated that EV nonetheless confirmed a excessive ORR in sufferers who have been cisplatin-ineligible; the indication was amended to require development on just one or extra prior line of therapy if a affected person was cisplatin-ineligible.²⁷ The part 3 randomized EV-301 trial confirmed the numerous OS and PFS advantage of EV monotherapy vs taxane or vinflunine and led to full FDA approval.²⁸ The mix of EV and pembrolizumab has been studied and will likely be mentioned later.

EV is initially dosed at 1.25 mg/kg, capping at 100 kg of physique weight, and is diminished stepwise by 0.25 mg/kg per dose stage to a minimal of 0.5 mg/kg for adversarial impact intolerability.²⁴ As a single agent, it’s administered on days 1, 8, and 15 of a 28-day cycle.²⁴ The one advisable preliminary pre-medications are anti-emetics. Widespread AEs for EV embrace pores and skin reactions like maculopapular rash, dry eyes, peripheral sensory neuropathy, and diarrhea.²⁴ Extreme pores and skin response incidence is greater than 10%, and sufferers with quickly evolving pores and skin reactions ought to be evaluated instantly, as doubtlessly deadly Stevens-Johnson syndrome (SJS) and Poisonous Epidermal Necrolysis (TEN) have occurred, most ceaselessly with the primary cycle.²⁴ Pneumonitis/interstitial lung or ocular problems together with imaginative and prescient adjustments could happen hardly ever.²⁴ EV ought to be held if a affected person’s labs on the day of infusion present hyperglycemia that’s larger than 250 mg/dL, as diabetic ketoacidosis can develop.²⁴ MMAE is hepatically metabolized by CYP3A4, so further consideration ought to be given to sufferers with liver cirrhosis/dysfunction.²⁴

Pembrolizumab and Enfortumab Vedotin-efjv

The mix of pembrolizumab and EV first obtained accelerated approval in 2023 as preliminary therapy for LA/mUC in cisplatin-ineligible sufferers based mostly on constructive outcomes from the part 1b/2 open-label EV-103/KEYNOTE-869 trial.29,30 In late 2023, the landmark part 3, international, open-label randomized EV-302/KEYNOTE-A39 trial demonstrated a dramatic OS and PFS profit for sufferers handled with pembrolizumab-EV as frontline remedy vs platinum (cisplatin or carboplatin) plus gemcitabine.³¹ The FDA authorized pembrolizumab-EV as therapy in any affected person identified with LA/mUC in late 2023 forward of the complete publication of EV-302/KEYNOTE-A39, and that is thought of the popular frontline routine in la/mUC.^4,32 These developments signify a serious leap ahead within the administration of LA/mUC and the primary time {that a} non-platinum antineoplastic therapy outperformed platinum-containing chemotherapy on this setting.³¹ Nevertheless, the OS and PFS profit from the addition of nivolumab to cisplatin/gemcitabine in CheckMate 901 can’t be immediately in comparison with the outcomes of EV-302/KEYNOTE-A39, so it could nonetheless be applicable to think about platinum-containing chemotherapy for preliminary administration in choose sufferers with concern concerning EV use, or if there is no such thing as a entry to EV + pembrolizumab (exterior US).⁴ Particular person affected person traits and affected person preferences may assist information alternative of preliminary remedy.

Together, pembrolizumab and EV are administered on a 21-day cycle with EV administered on days 1 and eight, and pembrolizumab is given solely on day 1 every cycle.²⁴ The one advisable preliminary pre-medications are anti-emetics, primarily for EV. Because of completely different anti-cancer mechanisms, clinicians should contemplate that sufferers could expertise AEs according to each EV and pembrolizumab, together with doubtlessly overlapping AEs, like pores and skin toxicity, diarrhea, or pneumonitis.²⁴ Greater incidence of sure AEs when in comparison with single-agent therapy could also be seen; peripheral neuropathy is a serious purpose for EV dose changes.²⁴

Sacituzumab Govitecan-hziy

Sacituzumab govitecan-hziy (SG, Trodelvy; Gilead Sciences Inc) is an ADC of the Trop-2-targeting antibody sacituzumab linked to the cytotoxic topoisomerase I inhibitor, SN-38.³³ In 2021, SG presently was granted accelerated approval for LA/mUC that has progressed on platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor based mostly on outcomes from the only arm part 2 TROPHY-U-01 cohort 1 trial (NCT03547973).^34,35

SG is run initially at 10 mg/kg on days 1 and eight of a 21-day cycle till development or unacceptable toxicity.³⁴ Sufferers ought to be pre-medicated with antiemetics, in addition to an antipyretic and histamine-1 and histamine-2 antagonists as infusion reactions could happen.³⁴ Corticosteroids can be utilized as pre-medication for sufferers who had prior infusion response and/or as an antiemetic.³⁴

SN-38 is primarily metabolized by uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1), so drug interactions can happen, and a few sufferers are “poor metabolizers” who’re at elevated threat for hematologic toxicity, diarrhea, and different AEs.³⁴ Testing for UGT1A1 genetic variants is recommended in sufferers who expertise extreme AEs, particularly early in therapy. Use of granulocyte-colony stimulating components as major prophylaxis ought to be thought of to cut back the chance of febrile neutropenia, which occurred in 10% of sufferers in TROPHY-U-01.³⁵ Dose discount for insupportable or extreme AEs is completed by administering dose ranges of seven.5 mg/kg or 5 mg/kg.³⁴ Extreme diarrhea and hematologic toxicity can happen no matter UGT1A1 genetic variants, and different AEs embrace fatigue, alopecia, mucositis, rash, and laboratory abnormalities, reminiscent of adjustments in liver operate checks.³⁴

Fam-Trastuzumab Deruxtecan-nxk

Fam-Trastuzumab Deruxtecan-nxk (T-DXd, Enhertu; Daiichi-Sankyo, Inc) is a human epidermal development issue 2 (HER2)–directed antibody and topoisomerase inhibitor conjugate beforehand authorized for less than breast, gastric, and non-small cell lung cancers, however extra lately additionally broadly for therapy of adults with metastatic or unresectable stable tumors which are HER2-positive as decided by a rating of three+ by immunohistochemistry (IHC) and who obtained 1 or extra systemic therapy or are with out “passable” various remedies.36 That is presently an accelerated approval. The open-label, part 2 DESTINY-PanTumor02 trial (NCT04482309) demonstrated PFS and OS advantages in sufferers handled with T-DXd.³⁷ Sufferers enrolled had quite a lot of tumors together with endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and others, and have been stratified in accordance with HER2 expression stage (1+, 2+, 3+) as decided by IHC and utilizing ASCO/School of American Pathology tips for scoring HER2 in gastric most cancers.³⁷ Sufferers with HER2 3+ expression had the longest median OS profit.³⁷ T-Dxd could also be thought of for sufferers with HER2-positive 3+ LA/mUC after development on prior therapy, or if they’re deemed to haven’t any higher options.⁴

For its tumor agnostic indication, T-DXd is dosed initially at 5.4 mg/kg each 21-day cycle.³⁸ Stepwise dose stage reductions for toxicities are authorized.38 Deruxtecan is primarily metabolized by CYP3A4.38 Left ventricular ejection fraction ought to be monitored earlier than initiation and periodically throughout therapy.³⁸ T-DXd is very emetogenic and sufferers ought to obtain applicable anti-emetics previous to and after infusion.³⁸ Different frequent AEs embrace diarrhea, fatigue, neutropenia, thrombocytopenia, hair thinning/loss, belly ache, musculoskeletal ache, and elevations in aminotransferases.^37,38 Extreme interstitial lung illness can happen, so sufferers ought to be endorsed on threat and presentation, and they need to be instructed to instantly report signs.³⁸

Conclusion

The panorama for LA/mUC has modified dramatically with the implementation of ICIs and novel focused therapies. The mix of pembrolizumab/EV is transformative, whereas different combos look promising. Ongoing scientific trials proceed to discover these anticancer therapies and different novel investigational brokers and combos, and there’s optimism that our armamentarium will proceed to extend and outcomes to enhance.

Acknowledgments

Thanks to Petros Grivas, MD, PhD for overview of this text for content material accuracy.

References

1. Siegel RL, Giaquinto AN, Jemal A. Most cancers statistics, 2024 [published correction appears in CA Cancer J Clin. 2024 Mar-Apr;74(2):203]. CA Most cancers J Clin.
2. Nationwide Most cancers Institute. Most cancers Stat Information: Bladder Most cancers. 2023. Accessed Might 8, 2024. https://seer.most cancers.gov/statfacts/html/urinb.html
3. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and threat components of urothelial bladder most cancers. Eur Urol. 2013;63(2):234-241.
4. NCCN. Scientific Follow Pointers in Oncology. Bladder most cancers, model 3.2024. Accessed Might 8, 2024. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
5. Galsky MD, Hahn NM, Rosenberg J, et al. Remedy of sufferers with metastatic urothelial most cancers “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432-2438.
6. Bellmunt J, Rodriguez-Vida A. Remedy of metastatic urothelial most cancers in 2018. JAMA Oncol. 2019;5(6):904.
7. Balversa. Prescribing Data. Janssen; 2024. Accessed Might 8, 2024. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/BALVERSA-pi.pdf
8. US Meals and Drug Administration. FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. April 12, 2019. Accessed Might 8, 2024. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma
9. Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Domestically Superior or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-348.
10. Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in superior or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961-1971.
11. Siefker-Radtke AO, Matsubara N, Park SH, et al. Erdafitinib versus pembrolizumab in pretreated sufferers with superior or metastatic urothelial most cancers with choose FGFR alterations: cohort 2 of the randomized part III THOR trial. Annals of Oncology. 2024;35(1):107-117.
12. Granier C, De Guillebon E, Blanc C, et al. Mechanisms of motion and rationale for using checkpoint inhibitors in most cancers. ESMO Open. 2017;2(2):e000213.
13. Eigentler TK, Hassel JC, Berking C, et al. Prognosis, monitoring and administration of immune-related adversarial drug reactions of anti-PD-1 antibody remedy. Most cancers Deal with Rev. 2016;45:7-18.
14. Marrone KA, Ying W, Naidoo J. Immune-Associated Antagonistic Occasions From Immune Checkpoint Inhibitors. Clin Pharmacol Ther. 2016;100(3):242-251.
15. NCCN. Scientific Follow Pointers in Oncology. Administration of Immunotherapy-Associated Toxicities, model 1.2024. Accessed Might 8, 2024.
16. Schneider BJ, Naidoo J, Santomasso BD, et al. Administration of immune-related adversarial occasions in sufferers handled with immune checkpoint inhibitor remedy: ASCO guideline replace. JCO. 2021;39(36):4073-4126.
17. Bavencio. Prescribing Data. EMD Serono; 2024. Accessed Might 8, 2024. https://www.emdserono.com/us-en/pi/bavencio-pi.pdf
18. Powles T, Park SH, Voog E, et al. Avelumab upkeep remedy for superior or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218-1230.
19. US Meals and Drug Administration. FDA approves nivolumab together with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma. March 7, 2024. Accessed Might 8, 2024. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial
20. van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine-Cisplatin in Superior Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778-1789.
21. Bamias A, Davis ID, Galsky MD, et al. Atezolizumab monotherapy versus chemotherapy in untreated regionally superior or metastatic urothelial carcinoma (IMvigor130): remaining total survival evaluation from a randomised, managed, part 3 examine. Lancet Oncol. 2024;25(1):46-61.
22. Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or mixed with chemotherapy versus chemotherapy as first-line remedy for superior urothelial carcinoma (KEYNOTE-361): a randomised, open-label, part 3 trial. Lancet Oncol. 2021;22(7):931-945.
23. Opdivo. Prescribing Data. Bristol Myers Squibb; 2024. Accessed Might 8, 2024. https://packageinserts.bms.com/pi/pi_opdivo.pdf
24. Padcev. Prescribing Data. Seagen; 2023. Accessed Might 8, 2024. https://astellas.us/docs/PADCEV_label.pdf
25. US Meals and Drug Administration. FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial most cancers. December 19, 2019. Accessed Might 8, 2024. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer
26. Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Dying 1/Programmed Dying Ligand 1 Remedy. J Clin Oncol. 2019;37(29):2592-2600.
27. Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible sufferers with superior urothelial carcinoma (EV‑201): a multicentre, single-arm, part 2 trial [published correction appears in Lancet Oncol. 2021 Jun;22(6):e239]. Lancet Oncol. 2021;22(6):872-882.
28. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in beforehand handled superior urothelial carcinoma. N Engl J Med. 2021;384(12):1125-1135.
29. US Meals and Drug Administration. FDA D.I.S.C.O. Burst Version: FDA approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) for regionally superior or metastatic urothelial carcinoma. Might 3, 2023. Accessed Might 8, 2024. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-padcev-enfortumab-vedotin-ejfv-keytruda-pembrolizumab-locally
30. Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in beforehand untreated superior urothelial most cancers. JCO. 2023;41(1):22-31.
31. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Superior Urothelial Most cancers. N Engl J Med. 2024;390(10):875-888.
32. US Meals and Drug Administration. FDA approves enfortumab vedotin-ejfv with pembrolizumab for regionally superior or metastatic urothelial most cancers. December 15, 2023. Accessed Might 8, 2024. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer
33. Trodelvy. Prescribing Data. Gilead; 2024. Accessed Might 8, 2024. https://www.gilead.com/-/media/information/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf
34. US Meals and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan for superior urothelial most cancers. April 13, 2021. Accessed Might 8, 2024. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer
35. Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: A Section II Open-Label Research of Sacituzumab Govitecan in Sufferers With Metastatic Urothelial Carcinoma Progressing After Platinum-Primarily based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol. 2021;39(22):2474-2485.
36. US Meals and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive stable tumors. April 4, 2024. Accessed Might 21, 2024. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
37. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and security of trastuzumab deruxtecan in sufferers with her2-expressing stable tumors: major outcomes from the destiny-pantumor02 part ii trial. JCO. 2024;42(1):47-58.
38. Enhertu. Prescribing Data. Daiichi Sankyo; 2024. Accessed Might 21, 2024. https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true